Loading clinical trials...
Loading clinical trials...
Lamotrigine Extended-Release in Elderly Patients With Epilepsy
This study is being conducted to determine the safety and tolerability of lamotrigine (LTG) in elderly patients with epilepsy. This study will be carried out using an extended-release formulation of lamotrigine (LTG-XR) that will allow once-a-day dosing.
Age
65 - No limit years
Sex
ALL
Healthy Volunteers
No
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Gilbert, Arizona, United States
GSK Investigational Site
Litchfield Park, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Fresno, California, United States
GSK Investigational Site
Fullteron, California, United States
GSK Investigational Site
Irvine, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Pasadena, California, United States
Start Date
August 1, 2007
Primary Completion Date
July 1, 2010
Completion Date
July 1, 2010
Last Updated
January 18, 2017
122
ACTUAL participants
Lamotrigine
DRUG
Lead Sponsor
GlaxoSmithKline
NCT06700356
NCT02531880
NCT05871372
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions